Literature DB >> 1541691

Quality control in immunocytochemistry: experiences with the oestrogen receptor assay.

F T Bosman1, A F de Goeij, M Rousch.   

Abstract

AIMS: To evaluate the feasibility of an interlaboratory quality control programme in immunohistochemistry.
METHODS: Several pathology laboratories were asked to carry out immunohistochemical oestrogen receptor staining on a set of freeze dried cryostat sections of breast cancer tissue. The sections and protocols for staining and semi-quantitative scoring were mailed to the participating laboratories in two trials. The oestrogen receptor content of the breast cancer samples was determined by radioligand binding assay on the tumour cytosol.
RESULTS: In the first trial 11 laboratories (response rate 60%) participated. Eight (73%) of the participants scored within a 95% confidence interval and all but one correctly classified the tumour as receptor positive. In the second trial all 20 participating laboratories (response rate 55%) correctly scored one tumour sample as negative and 18 of them (90% of respondents) correctly classified the two other tumour samples as receptor positive. In a quantitative evaluation a histochemical score within 95% confidence interval limits was provided by eight (40%) and 12 (60%) of the participants.
CONCLUSIONS: Semiquantitative scoring of immunocytochemical staining is valuable for performing correlative inter-laboratory studies, although this scoring protocol may not be required for diagnosis or prognosis. Significant inter-laboratory variability exists, leading to qualitatively correct receptor classification in 100% of receptor negative and 80% of receptor positive cases, and quantitative agreement in only about half of the cases. The perceived variability is not caused by systematic differences in the choice of the immunocytochemical technique, or the mailing of freeze dried sections. Quality control programmes should be included in the standard procedures of each diagnostic immunohistochemistry laboratory.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541691      PMCID: PMC495649          DOI: 10.1136/jcp.45.2.120

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer.

Authors:  W Remmele; U Hildebrand; H A Hienz; P J Klein; M Vierbuchen; L J Behnken; B Heicke; E Scheidt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  Quality control in immunohistochemistry. Report of a workshop sponsored by the Biological Stain Commission.

Authors:  J M Elias; A M Gown; R M Nakamura; D C Wilbur; G E Herman; E S Jaffe; H Battifora; D J Brigati
Journal:  Am J Clin Pathol       Date:  1989-12       Impact factor: 2.493

3.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells.

Authors:  W J King; G L Greene
Journal:  Nature       Date:  1984 Feb 23-29       Impact factor: 49.962

4.  Reliability of steroid hormone receptor assays: an international study.

Authors:  V C Jordan; D T Zava; U Eppenburger; A Kiser; S Sebek; E Dowdle; Z Krozowski; R C Bennett; J Funder; I M Holdaway; J L Wittliff
Journal:  Eur J Cancer Clin Oncol       Date:  1983-03

5.  Cytochemistry of sex steroid receptors: a critique.

Authors:  K S McCarty; D S Reintgen; H F Seigler; K S McCarty
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

Review 6.  Determination of steroid hormone-dependency of tumours utilizing tissue sections. Survey of histochemical techniques and their application in surgical pathology.

Authors:  T F De Goeij; F T Bosman; E M Berns
Journal:  J Pathol       Date:  1986-07       Impact factor: 7.996

7.  Immunohistology of oestrogen receptor and D5 antigen in breast cancer: correlation with oestrogen receptor content of adjacent cryostat sections assayed by radioligand binding and enzyme immunoassay.

Authors:  D D Giri; V J Dangerfield; R Lonsdale; K Rogers; J C Underwood
Journal:  J Clin Pathol       Date:  1987-07       Impact factor: 3.411

8.  Standardization of steroid receptor assays in human breast cancer--IV. Long-term within- and between-laboratory variation of estrogen and progesterone receptor assays.

Authors:  A Koenders; S M Thorpe
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08

Review 9.  Oestrogen receptors in human breast cancer: review of histopathological correlations and critique of histochemical methods.

Authors:  J C Underwood
Journal:  Diagn Histopathol       Date:  1983 Jan-Mar

10.  The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.

Authors:  J M Howat; M Harris; R Swindell; D M Barnes
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

View more
  9 in total

1.  Oestrogen, progesterone, and androgen receptors in ovarian neoplasia: correlation between immunohistochemical and biochemical receptor analyses.

Authors:  H C van Doorn; C W Burger; P van der Valk; H M Bonfrèr
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

Authors:  P J van Diest; P van Dam; S C Henzen-Logmans; E Berns; M E van der Burg; J Green; I Vergote
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients.

Authors:  Luiz Gustavo Oliveira Brito; Viviane Fernandes Schiavon; Jurandyr Moreira de Andrade; Daniel Guimarães Tiezzi; Fernanda Maris Peria; Heitor Ricardo Cosiski Marana
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.

Authors:  A H Honkoop; P J van Diest; J S de Jong; S C Linn; G Giaccone; K Hoekman; J Wagstaff; H M Pinedo
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

5.  Asporin is a stromally expressed marker associated with prostate cancer progression.

Authors:  Annie Rochette; Nadia Boufaied; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Hayley C Whitaker; Antonio Ramos-Montoya; David E Neal; Alice Dragomir; Armen Aprikian; Simone Chevalier; Axel A Thomson
Journal:  Br J Cancer       Date:  2017-02-02       Impact factor: 7.640

6.  PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.

Authors:  Khalil Choucair; Joshua Ejdelman; Fadi Brimo; Armen Aprikian; Simone Chevalier; Jacques Lapointe
Journal:  BMC Cancer       Date:  2012-11-22       Impact factor: 4.430

7.  Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer.

Authors:  Sas Leen; Van Laere Steven; Dierick Anne Marie; Duwel Valérie; De Pauw Annemie; Van Den Eynden Gert; Van Dam Peter; Dirix Luc; Vermeulen Peter; Lardon Filip
Journal:  Patholog Res Int       Date:  2014-03-06

8.  Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.

Authors:  Patrick P Carriere; Shawn D Llopis; Anna C Naiki; Gina Nguyen; Tina Phan; Mary M Nguyen; Lynez C Preyan; Letitia Yearby; Jamal Pratt; Hope Burks; Ian R Davenport; Thu A Nguyen; KiTani Parker-Lemieux; Florastina Payton-Stewart; Christopher C Williams; Stephen M Boué; Matthew E Burow; Bridgette Collins-Burow; Aaron Hilliard; A Michael Davidson; Syreeta L Tilghman
Journal:  Int J Environ Res Public Health       Date:  2015-12-22       Impact factor: 3.390

9.  Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases.

Authors:  Ann-Kathrin Müller; Melanie Föll; Bianca Heckelmann; Selina Kiefer; Martin Werner; Oliver Schilling; Martin L Biniossek; Cordula Annette Jilg; Vanessa Drendel
Journal:  Neoplasia       Date:  2017-12-14       Impact factor: 5.715

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.